Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall
Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said
Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said